Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (101,219)	$ (26,637)	$ (25,681)
Adjustments to reconcile net loss to net cash (used in) provided by
Loss (gain) on equity investments	1,781	(4,108)	(943)
Noncash revenue from equity investments	(107)	(397)	(186)
Fair value adjustments	(11,359)	(28,263)	(9,922)
Depreciation	2,847	3,658	3,640
Stock-based compensation	26,490	10,545	2,193
Noncash research and development expenses	811	2,137	1,051
Noncash investment accretion	5,270	646	(506)
Loss on disposal of property and equipment	140
Decrease (increase) in assets:
Accounts receivable, net	(321)	(12,747)	(5,038)
Unbilled and other receivables	(5,187)	3,468	(1,556)
Reduction in the carrying amount of right of use assets	5,799	5,342	4,177
Prepaid expenses and other assets	(1,121)	187	410
(Decrease) increase in liabilities:
Accounts payable	(411)	4,882	(294)
Accrued payroll, taxes, and benefits	6,405	4,966	2,948
Deferred revenue	(1,028)	59,705	6,715
Lease liabilities	(2,949)	(5,417)	(4,025)
Other accrued liabilities	3,490	(1,210)	958
Net cash (used in) provided by operating activities	(70,669)	16,757	(26,059)
Cash flows from investing activities:
Purchases of property and equipment	(7,167)	(2,538)	(1,836)
Purchases of equity investments	(3,700)	(2,869)
Distribution from equity investment	375	4,582	943
Proceeds from sale of equity investments	15,735
Purchases of marketable securities	(414,802)	(519,668)	(110,187)
Proceeds from sale and maturity of marketable securities	392,747	138,772	57,225
Net cash used in investing activities	(16,812)	(381,721)	(53,855)
Cash flows from financing activities:
Issuances of common stock upon initial public offering, net		211,491
Issuances of common stock upon follow-on public offering, net		325,600
Issuances of Series E preferred stock, net			29,893
Issuances of common stock upon stock option exercise	7,927	4,183	549
Contribution by noncontrolling interest	25		100
Deferred offering costs			(1,858)
Net cash provided by financing activities	7,952	541,274	28,684
Net (decrease) increase in cash and cash equivalents and restricted cash	(79,529)	176,310	(51,230)
Cash and cash equivalents and restricted cash, beginning of year	202,796	26,486	77,716
Cash and cash equivalents and restricted cash, end of year	123,267	202,796	26,486
Supplemental disclosure of cash flow and noncash information
Cash paid for income taxes	448	381	139
Supplemental disclosure of non-cash investing and financing activities
Accrued deferred offering costs			2,142
Purchases of property and equipment in accounts payable	705	8	90
Acquisitions of right of use assets in exchange for lease obligations	$ 71,054	2,709	464
Right of use assets recognized on adoption			$ 16,475
Reclassification of deferred financing costs to additional paid-in capital		$ 1,858